ScholarIQanswers from OpenAlex & ORCID
Natalie S. Callander
ResearcherPublications, citations & collaboration network
Natalie S. Callander is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Natalie S. Callander have?
ScholarIQindexed works
Natalie S. Callander has 445 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Natalie S. Callander have?
ScholarIQcitation count
Natalie S. Callander has 16,364 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Natalie S. Callander?
ScholarIQh-index
Natalie S. Callander has an h-index of 62 in OpenAlex.
What is the i10-index of Natalie S. Callander?
ScholarIQi10-index
Natalie S. Callander has an i10-index of 171 in OpenAlex.
What is the ORCID of Natalie S. Callander?
ScholarIQorcid
The ORCID for Natalie S. Callander is on the source record.
What is the OpenAlex record for Natalie S. Callander?
ScholarIQopenalex
The OpenAlex for Natalie S. Callander is on the source record.
What are the most-cited papers on Natalie S. Callander?
ScholarIQmost cited works
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
Sagar Lonial, Hans C. Lee, Ashraf Badros, Suzanne Trudel, Ajay K. Nooka, Ajai Chari, Al‐Ola Abdallah, Natalie S. Callander, Nikoletta Lendvai, Douglas W. Sborov, Attaya Suvannasankha, Katja Weisel, Lionel Karlin, Edward N. Libby, Bertrand Arnulf, Thierry Façon, Cyrille Hulin, K. Martin Kortüm, Paula Rodríguez‐Otero, Saad Z. Usmani, Parameswaran Hari, Rachid Baz, Hang Quach, Philippe Moreau, Peter M. Voorhees, Ira Gupta, Axel Hoos, Eric Zhi, January Baron, Trisha Piontek, Eric Lewis, Roxanne C. Jewell, Elisha J. Dettman, Rakesh Popat, Simona Degli Esposti, Joanna Opalinska, Paul G. Richardson, Adam D. Cohen
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
Paula Rodríguez‐Otero, Sikander Ailawadhi, Bertrand Arnulf, Krina K. Patel, Michèle Cavo, Ajay K. Nooka, Salomon Manier, Natalie S. Callander, Luciano J. Costa, Ravi Vij, Nizar J. Bahlis, Philippe Moreau, Scott R. Solomon, Michel Delforge, Jesús G. Berdeja, Anna Truppel-Hartmann, Zhihong Yang, Linda Favre‐Kontula, Fan Wu, Julia Piasecki, Mark Cook, Sergio Giralt
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial
Shaji Kumar, Susanna Jacobus, Adam D. Cohen, Matthias Weiss, Natalie S. Callander, Avina K. Singh, Terri L. Parker, Alexander Menter, Xuezhong Yang, Benjamin M. Parsons, Pankaj Kumar, Prashant Kapoor, Aaron S. Rosenberg, Jeffrey A. Zonder, Edward A. Faber, Sagar Lonial, Kenneth C. Anderson, Paul G. Richardson, Robert Z. Orlowski, Lynne I. Wagner, S. Vincent Rajkumar